Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists,E5564 and E5531

Abstract

The synthetic antagonists of lipopolysaccharide (LPS), E5531 and E5564, are analogs of the lipid A portion of LPS that not only lack agonistic activity but also inhibit the biological effects of LPS both in vitro and in vivo. The effects of LPS and these synthetic antagonists have been localized to the recently described Toll-like receptor 4 (TLR4). A recent report indicated that the naturally occurring LPS antagonist Rhodobacter sphaeroides LPS loses its antagonist properties and gains pro-inflammatory qualities in the presence of chlorpromazine and other amphipathic drugs. To determine whether these reported actions occur with our chemically defined LPS antagonists, we examined the effects of chlorpromazine, fluphenazine, trifluoperazine, and lidocaine on the antagonism elicited by RsLPS and E5531 in U373 cells, which produce IL-6 in response to LPS. We also tested the effects of these amphipathic molecules on the LPS-neutralizing activity of RsLPS and E5564 on LPS-induced TNF-α release in human whole blood. The results indicate that neither chlorpromazine, fluphenazine, trifluoperazine nor lidocaine alter the activity of E5531 or E5564 in an in vitro cell system or human whole blood. Furthermore, chlorpromazine did not affect the antagonistic activity of RsLPS or E5564 on IL-6 generation by peripheral blood mononuclear cells. Thus, based on these data, our purified synthetic LPS-antagonists do not appear to lose their antagonistic properties and/or become agonists in the presence of amphipathic agents or drugs.

References

Rossignol DP , Hawkins LD , Kishi Y. et al. Synthetic endotoxin antagonists. In: Brade H , Opal SM , Vogel SN , Morrison DC. (Eds) Endotoxin in Health and Disease. New York, NY: Marcel Dekker, 1999; 699—717.

Christ WJ , Asano O. , Robidoux AL et al. E5531, a pure endotoxin antagonist of high potency. Science 1995; 268: 80—83.

Kawata T. , Bristol JR , Rossignol DP et al. E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide. Br J Pharmacol 1999; 127: 853—862.

Kobayashi S. , Kawata T. , Kimura A. et al. Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist. Antimicrob Agents Chemother 1998; 42: 2824—2829.

Chow JC , Young DW , Golenbock DT , Christ WJ , Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction . J Biol Chem 1999; 274: 10689—10692.

Poltorak A. , He X. , Smirnova I. et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085—2088.

Hoshino K. , Takeuchi O. , Kawai T. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product . J Immunol 1999; 162: 3749—3752.

Thieblemont N. , Thieringer R. , Wright SD Innate immune recognition of bacterial lipopolysaccharide: dependence on interactions with membrane lipids and endocytic movement. Immunity 1999; 8: 771—777.

Frey EA , Miller DS , Jahr TG et al. Soluble CD14 participates in the response of cells to lipopolysaccharide . J Exp Med 1992; 176: 1665—1671.

10.

Hirschfeld M. , Kirschning CJ , Schwandner R. et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999; 163: 2382—2386.

11.

Schletter J. , Heine H. , Ulmer AJ , Rietschel ET Molecular mechanisms of endotoxin activity . Arch Microbiol 1995; 164: 383—389.

12.

Sheetz MP , Singer SJ Biological membranes as bi-layer couples. A molecular mechanism of drug-erythrocyte interactions. Proc Natl Acad Sci USA 1974; 71: 4457-—4461.

13.

Poltorak A. , Ricciardi-Castagnoli P. , Citterio S. , Beutler B. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000; 97: 2163—2167.

14.

Lien E. , Means TK , Heine H. et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497—504.

15.

Christ WJ , McGuinness PD , Asano O. et al. Total synthesis of the proposed structure of Rhodobacter sphaeroides lipid A resulting in the synthesis of new potent lipopolysaccharide antagonists . J Am Chem Soc 1994; 116: 3637—3638.

16.

Kopp EB , Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999; 11: 13—18.

17.

Yang RB , Mark MR , Gurney AL , Godowski PJ Signaling events induced by lipopolysaccharide-activated toll-like receptor 2. J Immunol 1999; 163: 639—643.

18.

Lien E. , Chow JC , Hawkins LD et al. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/ Toll-like receptor 4 signaling pathway. J Biol Chem 2001; 276: 1873—1880